- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192526
Serum Cholinesterase Level in Aluminum Phosphide Poisoning, the Possible Proposing Role of Atropin & Pralidoxime (ALPH)
May 11, 2020 updated by: Doaa Mohamed Abd El-Rahman, Assiut University
Assessment of Serum Cholinesrtrase Level in Aluminum Phosphide Poisoning Cases, the Possible Proposing Role of Atropine and Pralidoxime in Saving the Cases: Clinical and
Metal phosphides are widely used as a rodenticide and insecticide and poisoning with these substances has a very high mortality.
The aim of this study was to evaluate the butyrylcholinesterase (BuCh) level in poisoning with metal phosphides.
Study Overview
Status
Unknown
Conditions
Detailed Description
Today, the use of pesticides in the world is considered as a recognized health It is estimated that around 30% of global suicides are due to pesticide self-poisoning .
Metal phosphides pesticides are highly toxic, low cost, and are easily accessible as rodenticide agents and used for self-poisoning .
aluminum phosphide (ALP) are among the most important metal phosphides.
Poisoning with these agents is frequently seen in India, Srilanka and Iran.
In a recent study, the incidence of fatal aluminum phosphide poisoning cases referred for phosphine analysis was 5.22 and 37.02 per million of population of Tehran, Iran in 2006 and 2013, respectively (9).The mechanism of toxicity is not clearly defined.
ALP toxicity is related to the production of phosphine gas.
Phosphine inhibits cytochrome c oxidase and causes mitochondrial destruction and inhibits oxidative respiration which leads to anaerobic metabolism, severe metabolic acidosis, multi-organ dysfunction and death.
Phosphine can lead to severe cardiac suppression and cardiogenic shock.
One of the proposed mechanisms of toxicity is the reduction of the true cholinesterase and serum cholinesterase (butyrylcholinesterase) enzyme, but usually do not show obvious clinical manifestations .
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Assiut, Egypt
- AssiutU
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
cases of aluminum phosphide poisoning attending Assiut University Hospitals
Description
Inclusion Criteria: cases of aluminum phosphide poisoning -
Exclusion Criteria: concomitant ingestion
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
persistent cholineastrase inhibition is one of the pathological pathway of the ALP poisoning
Time Frame: 3 months
|
definite assessment of the pathogenesis of ALP helps in applying adaquqte treatment regmin
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Doaa Abd el rahman, AssiutU, faculty of medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2019
Primary Completion (Actual)
April 30, 2020
Study Completion (Anticipated)
July 30, 2020
Study Registration Dates
First Submitted
December 6, 2019
First Submitted That Met QC Criteria
December 6, 2019
First Posted (Actual)
December 10, 2019
Study Record Updates
Last Update Posted (Actual)
May 13, 2020
Last Update Submitted That Met QC Criteria
May 11, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- serum cholinestrase in AP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Toxicity;Chemical
-
SRI InternationalRecruitingToxicity;ChemicalUnited States
-
Baxalta now part of ShireDynPort Vaccine Company LLC, A GDIT CompanyCompletedHealthy Volunteers | Chemical Terrorism | Chemical WarfareUnited States
-
Sun Yat-sen UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
HealthpointWithdrawn
-
Assaf-Harofeh Medical CenterUnknown
-
Assistance Publique - Hôpitaux de ParisMission Interministérielle de Lutte contre les Drogues et les Conduites Addictives...Not yet recruitingCHEMICAL SUBMISSION
-
University Hospital, Gentofte, CopenhagenCompletedMultiple Chemical SensitivitiesDenmark
-
Cancer Institute and Hospital, Chinese Academy...UnknownChemotherapeutic Toxicity | Malignant Tumor | Liver InjuryChina